A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
对于淋巴瘤或慢性淋巴细胞白血病患者,第三剂抗SARS-CoV-2 mRNA疫苗并不能抵消抗CD20疗法和/或低免疫球蛋白水平带来的不利影响。
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2021.280026
Kohn, Milena; Delord, Marc; Chbat, Maureen; Guemriche, Amina; Merabet, Fatiha; Roupie, Anne-Laure; Lombion, Naelle; Farhat, Hassan; Longval, Thomas; Cabannes-Hamy, Aurélie; Lambert, Juliette; Marque-Juillet, Stéphanie; Raggueneau, Victoria; Osman, Jennifer; Spentchian, Marc; Rigaudeau, Sophie; Rousselot, Philippe; Besson, Caroline
SARS-CoV-2
淋巴瘤
白血病
CD20
细胞生物学
CD2
免疫/内分泌